Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

BACKGROUND: At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes even into adulthood. The objectives of this analysis were to d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Res Ther
Autors principals: Armaroli, Giulia, Klein, Ariane, Ganser, Gerd, Ruehlmann, Michael J., Dressler, Frank, Hospach, Anton, Minden, Kirsten, Trauzeddel, Ralf, Foeldvari, Ivan, Kuemmerle-Deschner, Jasmin, Weller-Heinemann, Frank, Urban, Andreas, Horneff, Gerd
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7597050/
https://ncbi.nlm.nih.gov/pubmed/33121528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02326-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars